Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Surgical Devices
aptusendo.com

See what CB Insights has to offer

Founded Year

2002

Stage

Acquired | Acquired

Total Raised

$96M

Valuation

$0000 

About Aptus Endosystems

Aptus Endosystems is a medical device company focused on developing advanced technology for endovascular aneurysm repair (EVAR). Aptus Endosystems has developed an endograft and helical anchor technology that allows physicians to perform minimally invasive EVAR while still providing the control and potential long term durability of an open surgical repair. The Fortevo AAA Endograft System and the HeliFX Aortic Securement System bear the CE Mark for distribution in the European Union. The HeliFX Aortic Securement System is cleared by the FDA for distribution in the United States. The Fortevo AAA Endograft System is Investigational Use Only in the United States.

Aptus Endosystems Headquarter Location

271 Gibraltar Drive

Sunnyvale, California, 94089,

United States

408-530-9050

Latest Aptus Endosystems News

Medtronic Showcases Aortic Leadership in Innovation with Clinical Release and Pipeline at VEITH 2015

Nov 16, 2015

Medtronic Acquires Aptus Endosystems "Leveraging decades of clinical experiences and data, our core technologies for treating abdominal aortic aneurysm (AAA) and descending thoracic disease, Endurant® and Valiant® product lines, have been proven in more than 280,000 patients globally," said Daveen Chopra, vice president and general manager of the Aortic business, which is part of the Aortic & Peripheral Vascular division at Medtronic. "Our mission to improve patient outcomes drives our commitment to build on our success and invest in complementary innovative technology that will allow physicians to treat more complex aortic disease. " The VEITHsymposium will begin with a special session focusing on new developments in AAA and endovascular aneurysm repair (EVAR). This session will feature the highly anticipated four-year subset results on hostile neck anatomies from the ENGAGE Global Registry for Medtronic's Endurant AAA stent graft system. Verhagen, M.D., Ph.D., Professor and Chief of Vascular Surgery, Erasmus University Medical Center in Rotterdam, the Netherlands, will present this real-world data on the opening day of VEITH. Additionally, four-year results from the full ENGAGE registry cohort will be presented on Saturday, November 21, 2015, by Marc R.H.M van Sambeek, M.D., Ph.D, Department of Vascular Surgery, Catharina Hospital, Eindhoven, the Netherlands. Medtronic's recently acquired EndoAnchor system will also be highlighted in nine presentations examining clinical applicability. The Heli-FX® EndoAnchor® system is an endovascular deployed anchor designed to attach a variety of aortic endografts to the native vessel wall. Finally, several Medtronic products in clinical trials will be highlighted, such as the Endurant® Evo AAA stent graft system, as well as products for complex aortic disease, including: Modified Valiant devices used in the treatment of ascending arch disease. One-year results from the early feasibility of the Valiant "Mona LSA®" branch thoracic stent graft system. The initial experience in the treatment of thoracoabdominal with modified Medtronic stent grafts. Key Events: Tuesday, November 17 6:51 am - 6:56 am   Redefining Adverse Neck Morphology With Newer EVAR Devices Which Perform Better In Short, Angulated, and Large Diameter Necks And Those With A Thrombus Burden: What Are the Limits?, from the ENGAGE Registry 7:20 am - 7:25 am Endograft Repair Of Ascending Aortic Lesions And Type A Dissections With A Physician Sponsored IDE (PSIDE) For A Modified Valiant Device: Lessons Learned And What Are The Prospects For An Endograft-Valve Combined Device? Noon - 1 pm Treating Challenging Anatomies in TEVAR and EVAR. New York Hilton Midtown, Gramercy West 2nd Floor, a Medtronic sponsored event Wednesday, November 18 9:05am - 9:09 am DEBATE: EVAR With Short Necks Are Best Treated With Standard EVAR Using Newer Endograft Devices Thursday, November 19 7:46am - 7:51am Newly Modified Medtronic Endurant (Evo) Endograft (investigational device): Initial Clinical Experience And Advantages 10:17am - 10:22am A New Manifold Branched Endograft Device (investigational device) For Treating TAAAs And Other Complex Aortic Lesions: Concept, Advantages, Initial Clinical Experience 11:26am - 11:31am The Medtronic Branched TEVAR Endograft, The Valiant Mona LSA System (investigational device): Technique, Advantages and Results 3:40pm - 4:47pm Session 61: Preventing And Treating Migration and Endoleaks: Update on Heli-Fx EndoAnchors Details such as times, titles and locations are subject to change. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world. About VEITH symposium Now in its 42nd year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. For more information, please visit www.VEITHpress.org or contact Pauline T. Mayer at 631.979.3780. About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. -end-

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aptus Endosystems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aptus Endosystems is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,312 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Aptus Endosystems Patents

Aptus Endosystems has filed 19 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/13/2015

10/16/2018

Implants (medicine), Prosthetics, Vascular diseases, Diseases of the aorta, Vascular surgery

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/13/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/16/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Implants (medicine), Prosthetics, Vascular diseases, Diseases of the aorta, Vascular surgery

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.